Table 2.
CNS treatment.
| Protocol | AML-PPLLSG 83 | AML-PPLLSG 94 | AML-PPLLSG 98 | AML-BFM 2004 Interim | AML-BFM 2012 Registry |
|---|---|---|---|---|---|
| CNS irradiation | |||||
| Cycle | Consolidation phase 2 | SR Consolidation phase 2 | SR and HR during maintenance | No prophylactic CNS irradiation | |
| HR short postremission block | |||||
| Doses | 0–1 years 12 Gy, 1–2 years 15 Gy, >2 years 18 Gy |
0-1 years 12 Gy, 1–2 years 15 Gy, >2 years 18 Gy |
0–1 years no irradiation, 1–2 years 15 Gy, >2 years 18 Gy |
<15 months no irradiation, 15 to <24 months 15 Gy, ≥24 months 18 Gy |
No prophylactic CNS irradiation |
| Intrathecal therapy | |||||
| Cycle | consolidation phase 2 days 31, 38, 45, and 51 |
SR: consolidation phase 2 days 31, 38, 45, and 51 | SR: AIE days 1 and 8, AI days 1 and 6, haM days 0 and 6, HAE day 0; maintenance treatment once a week for the first 4 weeks |
cytarabine monotherapy: HAM, hAM, and HAE day 1 triple therapy (cytarabine, methotrexate, and prednizon): AIE days 1 and 8, AI or AI/2-CDA day 1, maintenance therapy days 1, 14, 28, and 42 |
|
| HR additional doses during AD and AE, and on days 1, 8, and 15 of a short postremission block | HR: additional dose HAM day 0 | ||||
CSN—central nervous system; SR—standard risk; HR—high risk. Cytarabine monotherapy: 0–1 year, 20 mg; 1–2 years, 26 mg; 2–3 years, 34 mg; >3 years, 40 mg. Triple therapy: cytarabine—0–1 year, 16 mg; 1–2 years, 20 mg; 2–3 years, 26 mg; >3 years, 30 mg; methotrexate—0–1 year, 6 mg; 1–2 years, 8 mg; 2–3 years, 10 mg; >3 years, 12 mg; prednizon—0–1 year, 4 mg; 1–2 years, 6 mg, 2–3 years, 8 mg; >3 years, 10 mg.